Mo Yang, Suja Rajan and Amalia M. Issa Cost effectiveness of gene expression profiling for early stage breast cancer Cancer 118
Article first published online: 22 FEB 2012 | DOI: 10.1002/cncr.27443
The authors evaluated the cost effectiveness of recurrence score-guided treatment using 2 commercially available gene expression profiling (GEP) tests from a third-party payer's perspective. A Markov model suggests that MammaPrint is a more cost-effective GEP test compared with Oncotype DX at a threshold willingness-to-pay of $50,000 per quality-adjusted life-year.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field